Antimikotiki in sarkoidoza
Abstract
Background: Previous studies on sarcoidosis have shown that the addition of an anti-fungal medication to the traditional treatment with corticosteroids improves treatment efficiency. It cannot be excluded that the effect is due to a stimulatory effect of the anti-fungal medication on the action of corticosteroids. To assess this possibility a study was undertaken where patients with sarcoidosis stage 2 were given an antifungal medication only. Material and methods: Study subjects (n=10) were recruited from newly diagnosed cases of sarcoidosis and observed for 3 months to reduce the risk of including patients with spontaneous regression of the disease. They were given an anti- fungal medication for 2–11 months and x-rays were taken before and every second month after starting the treatment. Diffusion capacity, serum angiotensin converting enzyme, and chitotriosidase were determined as markers of sarcoidosis activity. Results: There were improvements in the x-ray findings as well as the markers of sarcoidosis in 8 out of 10 patients. Two patients had an exacerbation of their disease after two months and they were given corticosteroids in addition to the anti-fungal medication. Comments: The results demonstrate that the beneficial effects of anti-fungal medication are specific and not caused by an improvement of corticosteroid efficacy. The findings provide a basis for larger clinical studies.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
